EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

COVID ‐19–Induced Narcolepsy Type I With Cataplexy: A Short Report

Torsten Vinding Merinder, Martin Langeskov-Christensen, Filip Kirov

Journal of Sleep Research · 2026-10 · 35 (5)

DOI: 10.1111/jsr.70372 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Sleep Research, online erschienen am 29.05.2026. Verfasst von Torsten Vinding Merinder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Viborg Regional Hospital, Viborg, Denmark. Hauptthemen laut MEDLINE: Cataplexy, COVID-19, Narcolepsy. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Narcolepsy type I is a rare neurological sleep disorder characterised by chronic excessive daytime sleepiness, cataplexy, and low orexin (hypocretin) levels. Infection with SARS ‐ CoV ‐2 has been linked to neurological and neuropsychiatric sequelae, but cases of post‐ COVID narcolepsy remain extremely uncommon. We report a previously healthy 42‐year‐old Caucasian female who developed excessive daytime sleepiness, cataplexy, and hypnagogic/hypnopompic hallucinations within 3 months of confirmed SARS ‐ CoV ‐2 infection. Polysomnography ( PSG ) showed disturbed nocturnal sleep with a high arousal index and periodic limb movements and mild sleep apnea, while the multiple sleep latency test ( MSLT ) showed a mean latency of 1 min with sleep‐onset rapid eye movement ( REM ) periods in all naps. Cerebrospinal fluid hypocretin was markedly reduced (< 40 ng/L), confirming narcolepsy type I. Following the diagnosis, medical treatment was initiated—with methylphenidate for hypersomnolence followed by venlafaxine for cataplexy, which led to a substantial symptomatic improvement, enabling a return to daily functioning. The case contributes to the minimal literature on narcolepsy following COVID ‐19 and supports hypotheses of autoimmune‐mediated destruction of hypocretin‐producing neurons triggered by viral infection. Clinicians should maintain a high index of suspicion for primary sleep disorders in patients with persistent fatigue and hypersomnolence after COVID ‐19, as early recognition and targeted treatment markedly improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CataplexyCOVID-19NarcolepsyAdultFemaleHumansOrexinsPolysomnography

Stichwörter der Autor:innen

COVID‐19excessive daytime sleepinesshypnagogic hallucinationshypocretin deficiencypost‐viral autoimmunitysleep–wake regulation

Substanzen

Orexins

Autor:innen und Institutionen

  • Department of Neurology, Viborg Regional Hospital, Viborg, Denmark.
  • Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Zitieren

APA

Merinder, T. V., Langeskov-Christensen, M., & Kirov, F. (2026). COVID ‐19–Induced Narcolepsy Type I With Cataplexy: A Short Report. Journal of Sleep Research, 35(5). https://doi.org/10.1111/jsr.70372

Vancouver

Merinder TV, Langeskov-Christensen M, Kirov F. COVID ‐19–Induced Narcolepsy Type I With Cataplexy: A Short Report. Journal of Sleep Research. 2026;35(5). doi:10.1111/jsr.70372

BibTeX
@article{Merinder2026,
  author = {Merinder, Torsten Vinding and Langeskov-Christensen, Martin and Kirov, Filip},
  title = {COVID ‐19–Induced Narcolepsy Type I With Cataplexy: A Short Report},
  journal = {Journal of Sleep Research},
  year = {2026},
  volume = {35},
  number = {5},
  doi = {10.1111/jsr.70372}
}
Kostenlos starten →